Angiotech Pharmaceuticals (ANP) 10-K 2010 FY Annual report

EXHIBIT 12

ANGIOTECH

RATIO OF EARNINGS TO FIXED CHARGES

	Year Ended December 31,
	2006		2007			2008			2009			2010
	(Dollars in Thousands)
Earnings:
Pre-tax income (loss) from continuing operations	$	20,115	$	(70,592	)	$	(754,068	)	$	(16,831	)	$	(66,885	)
Total Earnings	$	20,115	$	(70,592	)	$	(754,068	)	$	(16,831	)	$	(66,885	)
Fixed Charges:
Interest expense and amortization of capitalized expenses related to indebtedness	$	35,502	$	51,748		$	44,490		$	38,039		$	40,258
Interest within rent expense	$	700	$	800		$	1,167		$	1,067		$	1,100
Total Fixed Charges	$	36,202	$	52,548		$	45,657		$	39,106		$	41,358
Pre-tax income (loss) from continuing operations plus fixed charges	$	56,317	$	(18,044	)	$	(708,411	)	$	22,275		$	(25,527	)
Ratio of Earnings to Fixed Charges		1.6		—	(1)		—	(1)		0.6			—	(1)
Dollar amount of deficiency		n/a	$	70,592		$	754,068		$	16,831		$	66,885

⁽¹⁾ Our earnings during this period were insufficient to cover fixed charges and, accordingly, ratios are not presented.